Cyclin-dependent kinase pathways as targets for cancer treatment.

By G. Shapiro. Journal of Clinical Oncology, 2006

990 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cell cycle, CDKs and cancer: a changing paradigm (2009, background): “CDK inhibitors have been also considered as relevant drug candidates for cancer therapy owing to their potential role in restoring control of the cell cycl”
Biological determinants of endocrine resistance in breast cancer (2009, background): “, and some small-molecule CDK inhibitors have entered clinical trial”
Cyclin D as a therapeutic target in cancer (2011, background): “Early evidence of the high incidence of aberrant cyclin expression in myriad cancer types and the sensitivity of cancer cells to acute inhibition of cyclins or CDKs, including cyclin D1, led to programmes that aimed to develop small-molecule CDK inhibitors as therapeutic”
Cell cycle kinases as therapeutic targets for cancer (2009, background): “Consequently, chemicals that inhibit transcriptional CDKs could possess anticancer activity by augmenting apoptotic responses in cancer cells, particularly tumorous haematopoietic cells as their survival depends on the continuous expression of anti-apoptotic protein”